论文部分内容阅读
目的探讨进一步提高重型再生障碍性贫血 (SAA)疗效的方法。方法采用环孢霉素A(CsA)联合大剂量丙种球蛋白 (HDIG)静脉滴注治疗SAA 1 2例 (观察组 ) ,并以同期采用大剂量甲泼尼龙 (HDMP)和雄激素 (康力龙 )的常规方案治疗SAA 9例作为对照组并进行两组疗效比较。结果观察组的疗效明显优于常规治疗对照组 ,总有效率分别为 83 .3 %和 33 .3 % (P <0 .0 5) ,而且血象、骨髓象恢复较快 ,早期感染率也较低 ,分别为 41 .7%和 77.8% ,未出现不能耐受的毒副作用。结论CsA联合HDIG是治疗SAA安全、有效的方法
Objective To explore ways to further improve the efficacy of severe aplastic anemia (SAA). Methods A total of 12 cases of SAA were treated with intravenous cyclosporine A (CsA) and high dose gamma globulin (HDIG). The patients in the observation group were treated with high dose methylprednisolone (HDMP) and androgens SAA routine treatment of 9 cases as a control group and compared the efficacy of the two groups. Results The efficacy of the observation group was significantly better than that of the conventional treatment group, with a total effective rate of 83.3% and 33.3% (P <0.05), respectively. Moreover, the blood and bone marrow recovered faster and the early infection rate was also higher Low, respectively, 41.7% and 77.8%, did not appear intolerable side effects. Conclusion CsA combined with HDIG is a safe and effective method for the treatment of SAA